Fungin™ - Antifungal Reagent
Prevention and Elimination of Fungi
Fungin™ is used as a "routine addition" to eukaryotic cell culture media to prevent fungal contaminations. It can also be used to eliminate fungal contaminations. This antimycotic compound kills yeasts, molds and fungi by disrupting ionic exchange through the cell membrane.
Fungin™ is an excellent alternative to Amphotericin B, a polyene antifungal antibiotic. Unlike Amphotericin B, Fungin™ is a highly stable compound. Fungin™ is cell culture tested, and may be added to media containing commonly used antibacterial agents.
Product concentration: 10 mg/ml
Active concentration: from 10 μg/ml to 50 μg/ml
Highly stable and water soluble compound
Compatible with Pen-Strep solutions
No toxicity on treated cells and no deleterious effects on cell metabolism
Shipped at room temperature and still active after 6 days at 37 °C
Fungin™ is provided as a cell culture tested, sterile filtered light yellow solution at a concentration of 10 mg/ml. It is available in two pack sizes:
- 5 x 1.5 ml (75 mg)
- 1 x 20 ml ( 200 mg)
Fungin™ is used as a "routine addition" to eukaryotic cell culture media to prevent fungal (including yeast) contaminations in small or large-scale mammalian cell cultures. Fungin™ can also be used to eliminate fungal (including yeast) contaminations in eukaryotic cell cultures. It is effective against commonly found cell culture contaminants, such as Candida albicans and Aspergillus.
Fungin™ is an excellent alternative to Amphotericin B, a polyene antifungal antibiotic. Unlike Amphotericin B, Fungin™ is a highly stable compound and it does not need to be dissolved in toxic deoxycholate. Fungin™ provides maximum protection against fungal contamination with minimum cytotoxicity. Fungin™ is cell culture tested, and may be added to media containing commonly used antibacterial agents, such as penicillin and streptomycin (Pen-Strep). Its use has been cited in many publications.
Recent articles using InvivoGen Fungin™ - Antifungal Reagent
- 2016 - Virology., 493:247-54.
Female genital tract inflammation, HIV co-infection and persistent mucosal Human Papillomavirus (HPV) infections.
Kriek JM, Jaumdally SZ, Masson L, Little F, Mbulawa Z, Gumbi PP, Barnabas SL, Moodley J, Denny L, Coetzee D, Williamson AL, Passmore JA.
- 2016 - Ann Biomed Eng., 44(4):1061-71.
Improved geometry of decellularized tissue engineered heart valves to prevent leaflet retraction.
Sanders B, Loerakker S, Fioretta ES, Bax DJ, Driessen-Mol A, Hoerstrup SP, Baaijens FP.
- 2014 - J Biol Chem., 289(31):21694-705.
The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT.
Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG.
- 2014 - Breast Cancer Res., 16(4):R78.
MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers.
Krutilina R, Sun W, Sethuraman A, Brown M, Seagroves TN, Pfeffer LM, Ignatova T, Fan M.
- 2012 - Nature Genetics , 44, 170Ð173
ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis.
Helias V, Saison C, Ballif BA, Peyrard T, Takahashi J, Takahashi H, Tanaka M, Deybach JC, Puy H, Le Gall M, Sureau C, Pham BN, Le Pennec PY, Tani Y, Cartron JP, Arnaud L
|Unit Size||75 mg (5 x 1.5 ml vial)|
|Price||For price or distributor address,
please select your country